The role of preoperative chemotherapy for colorectal cancer metastases in the liver with the lack of RAS mutations


如何引用文章

全文:

详细

Colorectal cancer (CRC) is one of the most common malignancies, occupying the third place in the world among malignant tumors morbidity rate and the 4th place on the causes of death. Every year in the world there are diagnosed more than 1.3 millions of new cases of the disease. The mortality rate continues to be one of the most common causes in the structure of cancer incidence. In Russia, each year there are diagnosed more than 60 thousands of new cases of colorectal cancer. For the last time the incidence increased by 11%, out of them more than 17 thousands patients show newly diagnosed distant metastases. In the absolute majority of cases metastases in the liver are firstly detected in 2-3 years. Liver is the organ- the most commonly affected by metastases. Methods of medicinal treatment of CRC metastases are of great importance and allowed to greatly improve the life expectancy of patients. Median overall survival (OS) is 35-40 months. The one of the last achievement of the modern drug therapy of metastatic CRC was the appearance of the preparation Cetuximab. Blocking of the KRAS gene is a key compartment of the signaling pathways that transmit extracellular growth signals from the surface of the cell to the nucleus. Further signals are transmitted via the cascade into the cellular nucleus, regulating cell growth, proliferation, angiogenesis, invasion and metastasis. Results of the research of PRIME, PEAK and FIRE-3 confirm the advantage of supplement ofpanitumumab or cetuximab to chemotherapy regimens FOLFOX or FOLFIRI in patients with wild-type Ras.

作者简介

A. Lazarev

N.N. Blokhin Russian Cancer Research Center

Altai Branch Barnaul, 656049, Russian Federation

K. Mamontov

N.N. Blokhin Russian Cancer Research Center

Altai Branch Barnaul, 656049, Russian Federation

A. Kotelnikov

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

Sergey Khays

N.N. Blokhin Russian Cancer Research Center

Email: khayss@mail.ru
MD, senior researcher of the Department of the Surgery of Liver and Pancreas Barnaul, 656049, Russian Federation

V. Lubennikov

N.N. Blokhin Russian Cancer Research Center

Altai Branch Barnaul, 656049, Russian Federation

参考

  1. WHO, IARC GLOBOCAN. Cancer Incidence and Mortality Worldwide 2008 http://globocaniarc.fr
  2. Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2013 году. М.: Издательство МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России; 2013.
  3. Goldberg R.M., Sargent D.J., Morton R.F. et al. A randomized controlled trial of fluorouracil plus’leucovorin, irinotecan, and oxaliplatin com-binations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004; 22 (1): 23-30.
  4. Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan. fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004 3; 350(23): 2335-42.
  5. Falcone A., Ricci S., Brunetti I. et al. Phase III trial of infusionalfluo-rouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the GruppoOncologicoNordOvest. J. Clin. Oncol. 2007; 25 (13): 1670-6.
  6. Saltz L.B., Clarke S., Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008; 26 (12): 2013-9.
  7. Bokemeyer C., Bondarenko I., Hartmann I.T. et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as firsf-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol. 2011; 22 (7): 1535-46.
  8. Van Cutsem E. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 2011; 29 (15): 2011-9.
  9. Douillard J.Y. Final results from PRIME: randomized phase III study of panitumumab with FOIF0X4 for first-line treatment of metastatic colorectal cancer. Ann. Oncol. 2014; 25 (7): 1346-55.
  10. Heinemann V., von Weikersthal L.F., Decker T. et al. FOLFIRI plus cetux-imab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label,phase 3 trial. Lancet Oncol. 2014; 15: 1065-75.
  11. Stintzing S., Jung A., Rossius L., Modest D.P., L. Fischer von Weikersthal, Decker T. et al. Analysis ofKRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study ofFOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. In: 2013 European Cancer Congress. 2013: Abstr. 17.
  12. Schwartzberg L.S., Rivera F, Karthaus M. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracilleucovorin, and oxaliplatin (mFOLFOx6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol. 2014; 32: 2240-7.
  13. Peeters M. et al. Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (inCRC). J. Clin. Oncol. 2014; 32 (Suppl. 3): Abstr. LBA387.
  14. Adams R.A., Meade A.M., Seymour M.T. et al. Intermittenvs continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomized phase 3 MRC COIN trial. Lancet Oncol. 2011; 12 (7): 642-53.
  15. Maughan T.S., Adams R.A., Smith C.G. et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of randomized phase 3 MRC COIN trial. Lancet. 2011; 377 (9783): 2103-14.
  16. Tveit K., Guren T., Glimelius B. et al. Randomized phase III study of 5-flurouracil/folinate/oxaliplatin given continuously or intermittently with or without of cetuximab, as first-line therapy of metastatic colorectal cancer: the NORDIC VII study (NCT0014314), by the Nordic Colorectal Cancer Biomodulation Group. J. Clin. Oncol. 2011; 29 (Suppl. 4): Abstr. 365.
  17. Tabernero J., Pfeiffer P., Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist. 2008; 13(2): 113-9. doi: 10.1634/theoncologist.2007-0201.
  18. Lièvre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008; 26(3): 374-9.
  19. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2009; 27(5): 663-71.
  20. Rougier P., Mitry E. Targeted biotherapy: a revolution in the management of patients with colorectal cancer? Gastroenterol. Clin. Biol. 2009; 33(8-9): 672-80.

版权所有 © Eco-Vector, 2016


 


##common.cookie##